v3.25.2
Subsequent Events (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 11, 2026
Jul. 11, 2025
Dec. 10, 2024
Dec. 09, 2024
Nov. 07, 2024
Nov. 06, 2024
Jul. 31, 2025
Jun. 30, 2025
Dec. 09, 2024
Mar. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Jun. 30, 2025
Jun. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Oct. 31, 2024
Oct. 08, 2024
Sonnet BioTherapeutics Holdings, Inc. [Member]                                    
Warrants to purchase shares                           187,500        
Proceeds from offering                         $ 10,500,000          
Gross proceeds                         $ 7,803,453 $ 3,899,157 $ 3,896,577 $ 21,006,371    
Gross proceeds exercise of warrants                             $ 2,983,769 $ 849    
Sonnet BioTherapeutics Holdings, Inc. [Member] | Registered Direct Offering [Member]                                    
Offering price per share     $ 2.23                              
Proceeds from offering     $ 3,400,000                              
Sonnet BioTherapeutics Holdings, Inc. [Member] | Private Placement [Member]                                    
Offering price per share     $ 2.23                              
Sonnet BioTherapeutics Holdings, Inc. [Member] | Prefunded Warrant [Member] | Registered Direct Offering [Member]                                    
Number of shares sold     768,000                              
Warrants to purchase shares     317,325                              
Exercise price     $ 0.0001                              
Sonnet BioTherapeutics Holdings, Inc. [Member] | Prefunded Warrant [Member] | Private Placement [Member]                                    
Number of shares sold     127,500                              
Warrants to purchase shares     545,500                              
Exercise price     $ 0.0001                              
Sonnet BioTherapeutics Holdings, Inc. [Member] | Warrant [Member] | Registered Direct Offering [Member]                                    
Warrants to purchase shares     1,085,325                              
Exercise price     $ 2.10                              
Warrants term     5 years                              
Sonnet BioTherapeutics Holdings, Inc. [Member] | Warrant [Member] | Private Placement [Member]                                    
Warrants to purchase shares     673,000                              
Exercise price     $ 2.10                              
Warrants term     5 years                              
Sonnet BioTherapeutics Holdings, Inc. [Member] | Common Stock [Member]                                    
Issuance of shares                   98,846 1,050,500 163,281     167,987 104,159    
Underwriting Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Chardan Capital Markets LLC [Member]                                    
Number of shares sold         155,000                          
Proceeds from offering         $ 4,200,000                          
Underwriting Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Chardan Capital Markets LLC [Member] | Prefunded Warrant [Member]                                    
Warrants to purchase shares         956,111                          
Offering price per share         $ 4.4999                          
Exercise price         $ 0.0001                          
Transaction Agreement [Member] | Forecast [Member]                                    
Termination fee $ 2,500,000                                  
Reimbursement expenses 1,000,000                                  
Transaction Agreement [Member] | RORSCHACH I LLC [Member]                                    
Reimbursement expenses               $ 1,000,000                    
Aggregate gross proceeds percentage               7.00%                    
Transaction Agreement [Member] | RORSCHACH I LLC [Member] | Forecast [Member]                                    
Termination fee $ 2,500,000                                  
Subsequent Event [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member]                                    
Warrants to purchase shares             3,421,624                      
Proceeds from offering                 $ 7,700,000                  
Private placement             $ 2,000,000.0                      
Share price             $ 1.156                      
Gross proceeds offerings             $ 5,000,000.0                      
Warrants             50,000                      
Gross proceeds             10,500,000                      
Gross proceeds exercise of warrants             $ 3,000,000.0                      
Subsequent Event [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Dr Richard Kenney [Member]                                    
Number of shares sold             160,000                      
Warrants to purchase shares             86,505                      
Private placement             $ 200,000                      
Subsequent Event [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Common Stock [Member]                                    
Warrants to purchase shares             865,052                      
Exercise price             $ 1.156                      
Issuance of shares             1,730,104                      
Subsequent Event [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Common Stock [Member] | Dr Richard Kenney [Member]                                    
Warrants to purchase shares             320,000                      
Subsequent Event [Member] | Alkem Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member]                                    
Upfront payment receivable                                 $ 500,000 $ 1,000,000.0
Milestone payment receivable                                   $ 1,000,000.0
Net payment after tax withholdings                                 $ 400,000  
Subsequent Event [Member] | Underwriting Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Chardan Capital Markets LLC [Member]                                    
Number of shares sold           155,000                        
Proceeds from offering           $ 4,200,000                        
Subsequent Event [Member] | Underwriting Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Chardan Capital Markets LLC [Member] | Prefunded Warrant [Member]                                    
Warrants to purchase shares           956,111                        
Offering price per share           $ 4.4999                        
Subsequent Event [Member] | Underwriting Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Chardan Capital Markets LLC [Member] | Warrant [Member]                                    
Warrants to purchase shares           2,222,222                        
Offering price per share           $ 4.50                        
Subsequent Event [Member] | Definitive Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member]                                    
Proceeds from offering       $ 3,500,000                            
Subsequent Event [Member] | Definitive Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Registered Direct Offering [Member]                                    
Offering price per share       $ 2.23         $ 2.23                  
Subsequent Event [Member] | Definitive Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Private Placement [Member]                                    
Offering price per share       $ 2.23         $ 2.23                  
Subsequent Event [Member] | Definitive Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Warrant [Member] | Registered Direct Offering [Member]                                    
Warrants to purchase shares       1,085,325         1,085,325                  
Exercise price       $ 2.10         $ 2.10                  
Warrants term       5 years         5 years                  
Subsequent Event [Member] | Definitive Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Warrant [Member] | Private Placement [Member]                                    
Warrants to purchase shares       673,000         673,000                  
Exercise price     $ 2.10                              
Subsequent Event [Member] | Definitive Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Common Stock [Member] | Registered Direct Offering [Member]                                    
Number of shares sold       1,085,325                            
Subsequent Event [Member] | Definitive Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Common Stock [Member] | Private Placement [Member]                                    
Number of shares sold       673,000                            
Subsequent Event [Member] | Business Combination Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member]                                    
Private placement             $ 5,500,000                      
Convertible notes             $ 2,000,000.0                      
Subsequent Event [Member] | Business Combination Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Convertible Preferred Stock [Member]                                    
Number of shares sold             5,500                      
Subsequent Event [Member] | Business Combination Agreement [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Common Stock [Member]                                    
Number of shares sold             4,400,000                      
Warrants to purchase shares             8,800,000                      
Subsequent Event [Member] | Transaction Agreement [Member]                                    
Offering price per share   $ 1.25                                
Cash Acquired from Acquisition   $ 200,000,000.0                                
Dividends Payable, Amount Per Share   $ 1.25                                
Subscription agreement description   Pursuant to the terms of the Transaction Agreement, the amount of cash proceeds to Sonnet at the Closing from the Subscription Agreements, the Contribution Agreements and the Initial PIPE Offering (as defined below) must equal at least $50 million. Concurrently with the signing of the Transaction Agreement, the Company received commitments from investors to contribute $305 million in cash and 12.6 million of HYPE tokens. Of these commitments, affiliates of the Company committed $41 million of cash and 46,500 of HYPE tokens.                                
Transaction agreement description   Also pursuant to the terms of the Transaction Agreement, at the Closing the Company shall issue to the Advisor (as defined below) (i) that number of shares of Pubco Common Stock equal to 5% of the shares of Pubco Common Stock issued and outstanding, on a fully-diluted, as converted basis, immediately following the Effective Time and (ii) warrants (the “Advisor Warrants”) to purchase a number of shares of Pubco Common Stock equal to, in the aggregate, 15% of the fully diluted number of outstanding shares of Pubco Common Stock immediately after Closing. The Advisor Warrants will be exercisable for five years following the Closing, at an exercise price equal to (i) for one-third of the Advisor Warrants, $1.875, (ii) for one-third of the Advisor Warrants, $2.50 and (iii) for one-third of the Advisor Warrants, $3.75.                                
Subsequent Event [Member] | Transaction Agreement [Member] | RORSCHACH I LLC [Member]                                    
Offering price per share   $ 1.25                                
Cash Acquired from Acquisition   $ 200,000,000.0                                
Dividends Payable, Amount Per Share   $ 1.25                                
Subscription agreement description   Pursuant to the terms of the Transaction Agreement, the amount of cash proceeds to Sonnet at the Closing from the Subscription Agreements, the Contribution Agreements and the Initial PIPE Offering (as defined below) must equal at least $50 million. Concurrently with the signing of the Transaction Agreement, the Company received commitments from investors to contribute $305 million in cash and 12.6 million of HYPE tokens. Of these commitments, affiliates of the Company committed $41 million of cash and 46,500 of HYPE tokens.                                
Transaction agreement description   Also pursuant to the terms of the Transaction Agreement, at the Closing Pubco shall issue to the Advisor (as defined below) (i) that number of shares of Pubco Common Stock equal to 5% of the shares of Pubco Common Stock issued and outstanding, on a fully-diluted, as converted basis, immediately following the Effective Time and (ii) warrants to purchase a number of shares of Pubco Common Stock equal to, in the aggregate, 15% of the fully diluted number of outstanding shares of Pubco Common Stock immediately after Closing. The Advisor Warrants will be exercisable for five years following the Closing, at an exercise price equal to (i) for one-third of the Advisor Warrants, $1.875, (ii) for one-third of the Advisor Warrants, $2.50 and (iii) for one-third of the Advisor Warrants, $3.75.